PROC - Procaps Group S.A
Previous close
1.97
0 0%
Share volume: 105
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.97
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-3.43%
1 Month
-17.57%
3 Months
-24.81%
6 Months
-34.00%
1 Year
-49.62%
2 Year
-72.83%
Key data
Stock price
$1.97
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.89 - $4.95
52 WEEK CHANGE
-$0.50
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Ruben Minski
Region: US
Website: procapsgroup.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: procapsgroup.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
procaps group has experience in the development of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. we have direct presence in 13 countries in latin america and we have more than 5,000 collaborators working under a sustainable model. we develop, manufacture, and market over-the-counter (otc) and prescription drugs, nutritional supplements and high-potential clinical solutions.
Recent news